A slow lane for life-saving drugs Although venom components may have potential practical applications, the time between discovery and a drug being approved for human use can be over 20 years
In addition to cardiometabolic risk factor reduction, their additional effect at the cellular and cytokines levels is likely to contribute to reduction of inflammation, atherosclerosis, and plaque formation
Regular follow-up visits can help manage side effects, adjust insulin doses, and ensure the medication is working safely and effectively
Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes
Phase III trials were carried out as part of the SURPASS programme to investigate its therapeutic effectiveness (glycaemic control and body weight reduction) and safety/tolerability for the treatment of patients with type 2 diabetes [90, 91]
Persistent muscle cramping that does not respond to hydration and electrolyte repletion, or cramping that significantly disrupts sleep or daily function, warrants medical evaluation
